ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Sam Chun Dang Pharm. (000250.KQ)
Sam Chun Dang Pharm. stock price today, ATLAS forecast and fair value
Healthcare · Pharmaceuticals · KOSDAQ · South Korea
₩188,900▼ -5.17%
Prices as of Oct 26, 2026 · KRW
Chance of rising in 1 month
46%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Sam Chun Dang Pharm. in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Sam Chun Dang Pharm.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Sam Chun Dang Pharm. a 46% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between ₩159,670 and ₩213,209; in 9 out of 10, between ₩123,566 and ₩275,505. Estimated annual volatility is 83%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- ₩4.4T
- Market cap (USD)
- $3.3B
- 52-week high
- ₩941,000
- 52-week low
- ₩120,000
- Revenue (12 months)
- ₩177B
- Gross margin
- 46.9%
- Operating margin
- 6.0%
- Net margin
- -0.1%
- Beta
- 1.56
What this means
ATLAS does not publish a fair value for 000250.KQ right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks 000250.KQ has traded between ₩120,000 and ₩941,000. Today it is 79.9% below that high and 57% above its low.
Its beta is 1.56: it tends to move more than the market, both up and down.
About the company
Sam Chun Dang Pharm. Co., Ltd manufactures, distributes, imports, and exports pharmaceuticals in South Korea.
Want to see everything about Sam Chun Dang Pharm.?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Sam Chun Dang Pharm. do?
Sam Chun Dang Pharm. Co., Ltd manufactures, distributes, imports, and exports pharmaceuticals in South Korea.
What is the chance 000250.KQ goes up next month?
46%: close to a coin flip. In half of the simulated outcomes, 000250.KQ ends the month between ₩159,670 and ₩213,209.
How big is Sam Chun Dang Pharm. and what is its P/E ratio?
Sam Chun Dang Pharm.'s market capitalization is ₩4.4T. We do not show a P/E because it has no positive earnings to base one on.
How volatile is 000250.KQ?
ATLAS estimates annual volatility at 83%. In a typical month, half of the outcomes end between ₩159,670 and ₩213,209.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer